These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28086177)

  • 1. Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses.
    Bi-Mohammed Z; Wright NM; Hearty P; King N; Gavin H
    Drug Alcohol Depend; 2017 Feb; 171():122-131. PubMed ID: 28086177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: a cross-sectional survey of drug using prisoners.
    Wright NM; Mohammed Z; Hughes GJ
    Drug Alcohol Depend; 2014 Nov; 144():254-8. PubMed ID: 25305714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring prison buprenorphine misuse in the United Kingdom: a qualitative study of former prisoners.
    Tompkins CN; Wright NM; Waterman MG; Sheard L
    Int J Prison Health; 2009; 5(2):71-87. PubMed ID: 25759139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
    Favrod-Coune T; Baroudi M; Casillas A; Rieder JP; Gétaz L; Barro J; Gaspoz JM; Broers B; Wolff H
    Swiss Med Wkly; 2013; 143():w13898. PubMed ID: 24186493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
    Johanson CE; Arfken CL; di Menza S; Schuster CR
    Drug Alcohol Depend; 2012 Jan; 120(1-3):190-5. PubMed ID: 21862241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
    Wiegand TJ
    J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes in patients with opioid use disorder initiated by prescription: a systematic review protocol.
    Sanger N; Bhatt M; Zielinski L; Sanger S; Shahid H; Bantoto B; Samaan MC; de Souza R; Samaan Z
    Syst Rev; 2018 Jan; 7(1):16. PubMed ID: 29368662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of opioid maintenance treatment in prison settings: a systematic review.
    Hedrich D; Alves P; Farrell M; Stöver H; Møller L; Mayet S
    Addiction; 2012 Mar; 107(3):501-17. PubMed ID: 21955033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid misuse epidemic: Addressing opioid prescribing and organization initiatives for holistic, safe and compassionate care.
    Naegle M; ; Mitchell AM; ; Flinter M; ; Dunphy L; ; Vanhook P; ; Delaney KR;
    Nurs Outlook; 2017; 65(4):477-479. PubMed ID: 28821312
    [No Abstract]   [Full Text] [Related]  

  • 15. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits.
    Davis JM; Severtson SG; Bucher-Bartelson B; Dart RC
    Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):18-25. PubMed ID: 24130046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising opioid substitution therapy in the prison environment.
    Alam F; Wright N; Roberts P; Dhadley S; Townley J; Webster R
    Int J Prison Health; 2019 Dec; 15(4):293-307. PubMed ID: 31532339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.
    Bodkin C; Bondy S; Regenstreif L; Kiefer L; Kouyoumdjian F
    BMJ Open; 2021 Nov; 11(11):e048944. PubMed ID: 34794988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definitive urine drug testing in office-based opioid treatment: a literature review.
    Barthwell AG; Allgaier J; Egli K
    Crit Rev Toxicol; 2018 Nov; 48(10):829-852. PubMed ID: 30794024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.